MedTrace Logo

Immunmodulation in Patients With HHT

NCT02983253 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 124

Last updated 2019-12-20

No results posted yet for this study

Summary

Hereditary haemorrhagic telangiectasia (HHT), also known as Rendu-Osler-Weber syndrome, is an inherited multisystemic disorder. Literature suggests that HHT is often associated with higher frequency of infectious diseases.

The purpose of this study is to evaluate a variety of immunologic parameters in the blood serum of HHT patients in comparison to probands.

Conditions

  • Hereditary Haemorrhagic Telangiectasia (HHT)

Interventions

OTHER

blood sample

none, only laboratory tests on blood serum

Sponsors & Collaborators

  • University Hospital, Essen

    lead OTHER

Principal Investigators

  • Urban Geisthoff, Prof.Dr.med. · University Hospital, Essen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2019-10-31
Completion
2019-10-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02983253 on ClinicalTrials.gov